Inmune Financial Statements From 2010 to 2022

INMB
 Stock
  

USD 6.91  0.79  10.26%   

Inmune Bio financial statements provide useful quarterly and yearly information to potential Inmune Bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Inmune Bio financial statements helps investors assess Inmune Bio's valuation, profitability, and current liquidity needs.
Inmune Bio does not presently have any fundamental trends for analysis.
.
  
Check Inmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inmune main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Inmune financial statements analysis is a perfect complement when working with Inmune Bio Valuation or Volatility modules. It can also supplement Inmune Bio's financial leverage analysis and stock options assessment as well as various Inmune Bio Technical models . Please see the analysis of Inmune Bio Correlation against competitors.

Inmune Z Score Analysis

Inmune Bio's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current Inmune Bio Z Score

    
  3.4  
Most of Inmune Bio's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

According to the company's disclosures, Inmune Bio has a Z Score of 3.4. This is 49.63% lower than that of the Healthcare sector and about the same as Biotechnology (which currently averages 3.34) industry. The z score for all United States stocks is 61.01% higher than that of the company.

Inmune Bio Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Inmune Bio's current stock value. Our valuation model uses many indicators to compare Inmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inmune Bio competition to find correlations between indicators driving Inmune Bio's intrinsic value. More Info.
Inmune Bio is rated second overall in cash per share category among related companies. It is currently regarded as number one stock in shares owned by institutions category among related companies producing about  3.48  of Shares Owned by Institutions per Cash per Share. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Inmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inmune Bio's earnings, one of the primary drivers of an investment's value.

About Inmune Bio Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Inmune Bio income statement, its balance sheet, and the statement of cash flows. Inmune Bio investors use historical funamental indicators, such as Inmune Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Inmune Bio investors may use each financial statement separately, they are all related. The changes in Inmune Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Inmune Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Inmune Bio Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Inmune Bio. Please read more on our technical analysis and fundamental analysis pages.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Inmune Bio Correlation against competitors. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.